Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA. Issue 3 (14th February 2020)

• Record Type: Journal Article
• Authors: Parker, Helen; Ellison, Stuart M; Holley, Rebecca J; O'Leary, Claire; Liao, Aiyin; Asadi, Jalal; Glover, Emily; Ghosh, Arunabha; Jones, Simon; Wilkinson, Fiona L; Brough, David; Pinteaux, Emmanuel; Boutin, Hervé; Bigger, Brian W
• Is Part Of: EMBO molecular medicine. Volume 12:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-14
• Subjects: cognitive decline -- haematopoietic stem cell gene therapy -- inflammasome -- interleukin‐1 receptor antagonist -- mucopolysaccharidosis; Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201911185
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract: Mucopolysaccharidosis IIIA is a neuronopathic lysosomal storage disease, characterised by heparan sulphate and other substrates accumulating in the brain. Patients develop behavioural disturbances and cognitive decline, a possible consequence of neuroinflammation and abnormal substrate accumulation. Interleukin (IL)‐1β and interleukin‐1 receptor antagonist (IL‐1Ra) expression were significantly increased in both murine models and human MPSIII patients. We identified pathogenic mechanisms of inflammasome activation, including that disease‐specific 2‐O‐sulphated heparan sulphate was essential for priming an IL‐1β response via the Toll‐like receptor 4 complex. However, mucopolysaccharidosis IIIA primary and secondary storage substrates, such as amyloid beta, were both required to activate the NLRP3 inflammasome and initiate IL‐1β secretion. IL‐1 blockade in mucopolysaccharidosis IIIA mice using IL‐1 receptor type 1 knockout or haematopoietic stem cell gene therapy over‐expressing IL‐1Ra reduced gliosis and completely prevented behavioural phenotypes. In conclusion, we demonstrate that IL‐1 drives neuroinflammation, behavioural abnormality and cognitive decline in mucopolysaccharidosis IIIA, highlighting haematopoietic stem cell gene therapy treatment with IL‐1Ra as a potential neuronopathic lysosomal disease treatment. Synopsis: This study reports that IL‐1, stimulated by storage substrates, is a critical mediator in the mucopolysaccharidosis IIIA (MPSIIIA) inflammatory cascade. Haematopoietic stem cell gene therapy using IL‐1Ra, the natural antagonist of IL‐1, prevented cognitive and behavioural decline in mice. IL‐1 blockade in MPSIIIA mice via lentiviral dependent haematopoietic stem cell overexpression of IL‐1Ra corrected cognitive decline and reduced neuroinflammation. 2‐O‐sulphation of MPSIIIA heparan sulphate elicited production of TLR4 dependent IL‐1β. MPSIIIA primary and secondary storage substrates activated the inflammasome and induced secretion of IL‐1β. IL‐1β and IL‐1Ra are important immuno‐biomarkers in MPSIIIA patients and mice. Abstract : This study reports that IL‐1, stimulated by storage substrates, is a critical mediator in the mucopolysaccharidosis IIIA (MPSIIIA) inflammatory cascade. Haematopoietic stem cell gene therapy using IL‐1Ra, the natural antagonist of IL‐1, prevented cognitive and behavioural decline in mice.